Here, Origin’s Rich Quelch explores the potential benefits of basing drug prescription on pharmacogenomic data and how transitioning to such a system could impact the UK’s National Health Service.
The call for personalised prescribing is growing thanks to advancements in pharmacogenomics – our understanding of how a person’s unique genetic make-up affects their response to a medicine.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Today, up to 6.5 percent of UK hospital admissions are the result of an adverse reaction to a prescribed or over-the-counter drug. Moreover, up to half of people do not respond as intended.
In a recent report by the British Pharmacological Society and the Royal College of Physicians, adopting a pharmacogenomic model is hailed as a way to modernise the UK’s healthcare system, reduce costs and improve health outcomes across the board.
So, could we see personalised prescribing become integrated fully, fairly and swiftly into the UK’s National Health Service (NHS) in the near future?
An outdated model of prescribing
Everyone has different genetic information, stored in the genes they inherited from their parents. It is this unique data that pharmacogenomics uses to understand your response to different drugs and tailor them accordingly and, as your genes hardly change across your lifetime, only one blood test is needed to guide the choice and dose of medicine at any age or life stage.
However, the way the NHS prescribes medicines today is largely the same as when it first started over 70 years ago, despite huge leaps forward in the way it diagnoses and treats patients.
The status quo remains a one-size-fits-all approach to prescribing based on a universal understanding of their benefits to patients. But this ignores the (large) minority of patients who do not respond well to certain medicines.
Instead, moving towards a personalised prescribing model based on a patient’s genetic makeup and how they uniquely respond to different medicines and treatments, can allow healthcare providers to offer the right treatments, at the right time, in the right doses.
From common drugs like antibiotics and anti-inflammatory medicines, to advanced treatments like chemotherapy, a person’s genes can mean they experience negative and even life-threatening side effects. In the UK alone, there are hundreds of deaths each year caused by adverse drug reactions.
For others, they lack the gene that makes certain drugs, like the painkiller codeine, effective meaning they do not see an improvement. This not only wastes money and products but leaves a patient with untreated pain.
Pharmacogenomic research has also revealed a rare variation in one gene that can cause an excessive immune reaction when exposed to a variety of common medications, resulting in liver damage.
So, with the NHS at the limits of affordability and waiting lists at an all-time high, could pharmacogenomics offer the answer?
Making pharmacogenomic testing a reality
Using pharmacogenomic testing more widely within the NHS has the potential to keep more people healthier for longer, as well as save money and resources.
But achieving this will not be straightforward. The tests required are currently not widely available and there is a knowledge gap among patients, prescribers and health practitioners, meaning adoption remains low.
While the authors of the report call on NHS Trusts to move towards a pharmacogenomics model for prescribing, it is not as simple as testing patients when they arrive at a doctor’s surgery or hospital.
As set out by the British Pharmacological Society and the Royal College of Physicians, there are several recommendations that will help to make pharmacogenomic testing a reality across NHS Trusts.
They suggest that the move needs to be a gradual and iterative process to achieve a comprehensive service that is available in both primary and secondary care settings, as well as in specialised centres. Additionally, the body of knowledge surrounding gene-drug pairs needs to be refined and built on, with newly discovered pairs added into the NHS National Genomic Test Directory.
To avoid a postcode lottery of care and thereby exacerbate inequalities, mainstreaming pharmacogenomic services in the NHS throughout the UK should be commissioned and funded through the relevant pathways in the four nations rather than locally driven. The data collected across the four nations also needs to be standardised, reported, stored and shared to accelerate its usefulness and success.
The knowledge gap around personalised prescribing must be closed via a comprehensive education and training package aimed at all sectors of healthcare, as well as embedding pharmacogenomics into curricula for training the future workforce.
To achieve a multidisciplinary pharmacogenomics service, clinicians, general practitioners (GPs) and pharmacists need to be supported through clearly defined roles, consulting services sat within each integrated care system, and strategically planned service delivery models to incorporate workforce planning from the outset. This will ensure there are enough healthcare professionals to deliver the service within budget and to a high quality.
Finally, to be truly patient-centred, the implementation of pharmacogenomics needs to be accompanied by clear and open lines of communications with patient representative bodies, the public and the media.
Consent and ethics
As for any standard medical procedure, consent will need to be gained by each patient before pharmacogenomic testing can take place. The patient must have capacity, be appropriately informed and be free from coercion.
But for some, genetic data is believed to be ‘special’, deeply personal and different from other types of health or medical data. This belief could mean clinicians, GPs and pharmacists come up against strong resistance among some patients, making it difficult to obtain consent.
Guided by the National Genomic Test Directory, pharmacogenomics informed prescribing has the potential to be a daily prescribing reality across the UK, but it could be a significant amount of time before we see this available to everyone”
Implementation must also consider the diversity of our population and the fact that most genetic research up until this point has been based on patient groups with European ancestry. If diversity and differences in biological risk factors are overlooked, the roll out of pharmacogenomic testing and the development of a national framework could exacerbate existing health and race inequalities with damaging consequences. As the data grows, so too will our understanding of how biological factors influence our response to medicines and, ultimately, outcomes.
Lastly, any genomic data collected by the NHS as part of clinical care must be securely stored and kept confidential in line with the UK General Data Protection Regulation (GDPR). Any deviations or breaches must be communicated swiftly and transparently as set out by the legislations to avoid loss of public confidence and reduced engagement.
An exciting road ahead
It is clear there are many barriers, as well as opportunities, provided by increasing pharmacogenomic testing across the NHS.
The UK is at the forefront of a genomic revolution, having first undertaken the 100,000 Genomes Project, which is now aiming to extend to five million genomes. Guided by the National Genomic Test Directory, pharmacogenomics informed prescribing has the potential to be a daily prescribing reality across the UK, but it could be a significant amount of time before we see this available to everyone.
In the meantime, we can look forward to a time when the traditional model of care is fundamentally and irreversibly changed for the better, resulting in a personalised, fit for the times system.
About the author
Rich Quelch, Global Head of Marketing at Origin, is an experienced global marketer within the healthcare and pharmaceutical sector. He has led the development of the Origin brand, positioning it as a world-leading supplier of innovative and ground-breaking pharmaceutical packaging devices, as well as offering a unique supply chain model which is disrupting the pharma industry.
Established over 55 years ago, Origin offers customers a remarkable range of versatile packaging solutions that respond to the unique needs of the global pharmaceutical marketplace. Origin engages in the design, manufacture, and consolidated supply of pharmaceutical packaging, partnering with licence holders and CMOs.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.